Assessment of Serum Leptin in Vitiligo Patients

Study Overview
=================
Brief Summary
-----------------
Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index and disease dermographic data .

Detailed Description
-----------------
, leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators such as tumor necrosis factor α TNF, IL-2 and IL-6, as well as enhancing cytotoxic T cells CD8 recruitment and inhibiting the functions of regulatory T cells Tregs. Leptin can also aid in induction of oxidative stress by activating nicotinamide adenine dinucleotide phosphate (NADPH) oxidase• Venous blood samples will be taken from patients and controls to evaluate serum leptin: Morning samples will be taken after 12-h overnight fast in plain vacutainer tubes and directly centrifuged (1098 g for 15 min). Sera will be then collected in plain, capped, 5 ml centrifuge tubes Eppendorf and freezed at -20ᵒC in a well-monitored freezer until the analysis is performed• Serum leptin will be quantitatively assessed in vitro using DRG leptin Sandwich Enzyme Linked Immuno-Sorbent Assay ELISA. ELISA will be performed according to manufacturer's guidelines where each run included a standard curve. Using the mean absorbance value for each sample, the corresponding concentration from the standard curve will be determined.

Official Title
-----------------
Assessment of Serum Leptin in Vitiligo Patients

Conditions
-----------------
Vitiligo

Intervention / Treatment
-----------------
* Diagnostic Test: serum leptin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with vitiligo who are above the age of 18 years Exclusion Criteria: Patients with other autoimmune diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: group A<br>obese with vitligo | Diagnostic Test: serum leptin<br>* Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators<br>|
| Active Comparator: group b<br>obese without vitligo | Diagnostic Test: serum leptin<br>* Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators<br>|
| Active Comparator: group C<br>non obese with vitiligo | Diagnostic Test: serum leptin<br>* Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators<br>|
| Active Comparator: group D<br>non obese without vitiligo | Diagnostic Test: serum leptin<br>* Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| level of serum leptin | Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index and disease dermographic data . | 6 month |